Fumiyoshi Ohyanagi

1.4k total citations
68 papers, 1.1k citations indexed

About

Fumiyoshi Ohyanagi is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Fumiyoshi Ohyanagi has authored 68 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 47 papers in Pulmonary and Respiratory Medicine, 47 papers in Oncology and 14 papers in Molecular Biology. Recurrent topics in Fumiyoshi Ohyanagi's work include Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Fumiyoshi Ohyanagi is often cited by papers focused on Lung Cancer Treatments and Mutations (44 papers), Lung Cancer Research Studies (32 papers) and Lung Cancer Diagnosis and Treatment (18 papers). Fumiyoshi Ohyanagi collaborates with scholars based in Japan, United States and United Kingdom. Fumiyoshi Ohyanagi's co-authors include Makoto Nishio, Atsushi Horiike, Noriko Yanagitani, Takeshi Horai, Yuichi Ishikawa, Sakae Okumura, Satoru Kitazono, Ken Nakagawa, Hironori Ninomiya and Noriko Motoi and has published in prestigious journals such as Journal of Clinical Oncology, CHEST Journal and British Journal of Cancer.

In The Last Decade

Fumiyoshi Ohyanagi

64 papers receiving 1.1k citations

Peers

Fumiyoshi Ohyanagi

PRM

ONCOL

SURGE

Antonio Febbraro Italy

Michihiko Tajiri Japan

Arunee Dechaphunkul Thailand

Sung Hoon Sim South Korea

Seung‐Hoon Beom South Korea

Fausto Barbieri Italy

Ingo Alldinger Germany

Madoka Kimura Japan

Kazuhiko Shibata Japan

Takaaki Tokito Japan

Antonio Febbraro Italy

Fumiyoshi Ohyanagi

314 ×0.5

PRM

649 ×1.2

ONCOL

249 ×0.9

253 ×1.2

SURGE

241 ×1.2

Citations per year, relative to Fumiyoshi Ohyanagi Fumiyoshi Ohyanagi (= 1×) peers Antonio Febbraro

Countries citing papers authored by Fumiyoshi Ohyanagi

Since Specialization

Citations

This map shows the geographic impact of Fumiyoshi Ohyanagi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fumiyoshi Ohyanagi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fumiyoshi Ohyanagi more than expected).

Fields of papers citing papers by Fumiyoshi Ohyanagi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fumiyoshi Ohyanagi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fumiyoshi Ohyanagi. The network helps show where Fumiyoshi Ohyanagi may publish in the future.

Co-authorship network of co-authors of Fumiyoshi Ohyanagi

This figure shows the co-authorship network connecting the top 25 collaborators of Fumiyoshi Ohyanagi. A scholar is included among the top collaborators of Fumiyoshi Ohyanagi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fumiyoshi Ohyanagi. Fumiyoshi Ohyanagi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Okuma, Yusuke, Yasushi Goto, Fumiyoshi Ohyanagi, et al.. (2020). Phase II trial of S‐1 treatment as palliative‐intent chemotherapy for previously treated advanced thymic carcinoma. Cancer Medicine. 9(20). 7418–7427. 14 indexed citations

Yanagitani, Noriko, Ken Uchibori, Sumie Koike, et al.. (2020). Drug resistance mechanisms in Japanese anaplastic lymphoma kinase‐positive non–small cell lung cancer and the clinical responses based on the resistant mechanisms. Cancer Science. 111(3). 932–939. 41 indexed citations

Hasegawa, Tsukasa, Noriko Yanagitani, Fumiyoshi Ohyanagi, et al.. (2020). Phase II study of the combination of S-1 with bevacizumab for patients with previously treated advanced non-squamous non-small-cell lung cancer. International Journal of Clinical Oncology. 26(3). 507–514.

Nokihara, Hiroshi, Makoto Nishio, Noboru Yamamoto, et al.. (2018). Phase 1 Study of Cabozantinib in Japanese Patients With Expansion Cohorts in Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 20(3). e317–e328. 29 indexed citations

Nishikawa, Shingo, Rie Sakakibara, Ryo Ariyasu, et al.. (2018). EGFR T790M mutation after chemotherapy for small cell lung cancer transformation of EGFR-positive non-small cell lung cancer. Respiratory Medicine Case Reports. 24. 19–21. 12 indexed citations

Yanai, Takako, Satoru Iwasa, Hironobu Hashimoto, et al.. (2017). A double-blind randomized phase II dose-finding study of olanzapine 10 mg or 5 mg for the prophylaxis of emesis induced by highly emetogenic cisplatin-based chemotherapy. International Journal of Clinical Oncology. 23(2). 382–388. 48 indexed citations

Sakakibara, Rie, Kentaro Inamura, Yuichi Tambo, et al.. (2016). EBUS-TBNA as a Promising Method for the Evaluation of Tumor PD-L1 Expression in Lung Cancer. Clinical Lung Cancer. 18(5). 527–534.e1. 108 indexed citations

Suzuki, K., Takeharu Yamanaka, Hiroki Hashimoto, et al.. (2016). Randomized, double-blind, phase III trial of palonosetron versus granisetron in the triplet regimen for preventing chemotherapy-induced nausea and vomiting after highly emetogenic chemotherapy: TRIPLE study. Annals of Oncology. 27(8). 1601–1606. 61 indexed citations

Nishio, Makoto, Atsushi Horiike, Hiroshi Nokihara, et al.. (2015). Phase I study of the anti-MET antibody onartuzumab in patients with solid tumors and MET-positive lung cancer. Investigational New Drugs. 33(3). 632–640. 13 indexed citations

10.

Miyauchi, Eisaku, Noriko Motoi, Hiroshi Ono, et al.. (2015). Distinct Characteristics of Small Cell Lung Cancer Correlate With Central or Peripheral Origin. Medicine. 94(51). e2324–e2324. 28 indexed citations

11.

Harada, Hideyuki, Makoto Nishio, Haruyasu Murakami, et al.. (2013). Dose-Escalation Study of Three-Dimensional Conformal Thoracic Radiotherapy With Concurrent S-1 and Cisplatin for Inoperable Stage III Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 14(4). 440–445. 11 indexed citations

12.

Kudo, Keita, Fumiyoshi Ohyanagi, Eisaku Miyauchi, et al.. (2011). Clinicopathological findings of non-small-cell lung cancer with high serum progastrin-releasing peptide concentrations. Lung Cancer. 74(3). 401–404. 17 indexed citations

13.

Horiike, Atsushi, K. Kudo, Eisaku Miyauchi, et al.. (2011). Phase I study of irinotecan and gefitinib in patients with gefitinib treatment failure for non-small cell lung cancer. British Journal of Cancer. 105(8). 1131–1136. 10 indexed citations

14.

Ohyanagi, Fumiyoshi, Nobuyuki Yamamoto, Atsushi Horiike, et al.. (2009). Phase II trial of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer. British Journal of Cancer. 101(2). 225–231. 43 indexed citations

15.

Takahashi, Toshiaki, Fumiyoshi Ohyanagi, Atsushi Horiike, et al.. (2007). P2-217: Phase II study of TS-1(S) plus cisplatin(P) with concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology. 2(8). S658–S658. 2 indexed citations

16.

Horiike, Atsushi, Hideharu Kimura, Kazuto Nishio, et al.. (2007). Detection of Epidermal Growth Factor Receptor Mutation in Transbronchial Needle Aspirates of Non-Small Cell Lung Cancer. CHEST Journal. 131(6). 1628–1634. 78 indexed citations

17.

Ohyanagi, Fumiyoshi, Atsushi Horiike, Yoshio Okano, et al.. (2007). Phase II trial of gemcitabine and irinotecan in previously treated patients with small-cell lung cancer. Cancer Chemotherapy and Pharmacology. 61(3). 503–508. 14 indexed citations

18.

Ohyanagi, Fumiyoshi, Fumiko Taguchi, Takeshi Horai, et al.. (2006). Phase II Study of Combination Chemotherapy with Gemcitabine and Irinotecan in Patients with Advanced Non-Small-Cell Lung Cancer Previously Treated with Platinum-Containing Chemotherapy Regimens. Japanese Journal of Clinical Oncology. 36(9). 547–551. 4 indexed citations

19.

Nishio, Makoto, Fumiyoshi Ohyanagi, Yuichi Ishikawa, et al.. (2005). Gefitinib treatment affects androgen levels in non-small-cell lung cancer patients. British Journal of Cancer. 92(10). 1877–1880. 24 indexed citations

20.

Nishio, Makoto, Masanori Matsuda, Fumiyoshi Ohyanagi, et al.. (2005). Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy. Lung Cancer. 49(2). 245–251. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact